Clincosm LogoSign in Get a demo

SDA: Somatic Diseases in Autistic Children

Sponsor
University Hospital, Montpellier (Other)
Overall Status
Completed
CT.gov ID
NCT05077020
Collaborator
(none)
27
Enrollment
1
Location
21
Actual Duration (Months)
1.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

For many reasons, medical monitoring in autistic patients is very difficult. This study is designed to determine the prevalence of comorbid diseases (neurological, cardiac, digestive, dental diseases…) in patients suffering from ASD to prevent them or diagnose them earlier.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Mean goal : to determine the prevalence of comorbid diseases (neurological, cardiac, digestive, dental diseases…) in patients suffering from ASD to prevent them or diagnose them earlier.

    Secondary goals :

    • to obtain an objective assessment of the "general" monitoring in these patients (vaccinations, growth…)

    • to assess their habits (food, sleep, screen exposition)

    • to determine, in this monitoring and the habits, vigilance points which will need a specific pediatric consultation.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    27 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Medical Monitoring and Somatic Diseases in Children Who Suffer From Autism Spectrum Disorder (ASD)
    Actual Study Start Date :
    Jan 1, 2020
    Actual Primary Completion Date :
    Jan 1, 2021
    Actual Study Completion Date :
    Oct 1, 2021

    Outcome Measures

    Primary Outcome Measures

    1. Determine the prevalence of comorbid diseases [1 day]

      Determine the prevalence of comorbid diseases

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A to 18 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion criteria:
    • consultation after psychiatric evaluation
    Exclusion criteria:

    • age > 18 years

    • Impossibility to obtain the consent of parents / legal representatives.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Uhmontpellier Montpellier France 34295

    Sponsors and Collaborators

    • University Hospital, Montpellier

    Investigators

    • Study Director: Eric JEZIORSKI, University Hospital, Montpellier

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospital, Montpellier
    ClinicalTrials.gov Identifier:
    NCT05077020
    Other Study ID Numbers:
    • RECHMPL21_0556
    First Posted:
    Oct 13, 2021
    Last Update Posted:
    Oct 26, 2021
    Last Verified:
    Oct 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Disease
    Autistic Disorder
    Autism Spectrum Disorder

    Study Results

    No Results Posted as of Oct 26, 2021